Abstract
Ulinastatin has previously been used as a drug for patients with acute inflammatory disorders. The goal of the present study was to investigate the protective effects of ulinastatin on myelin sheaths and oligodendrocytes in experimental autoimmune encephalomyelitis (EAE), and to explore the possible underlying mechanism. Mice were divided into an ulinastatin treatment group, a normal saline treatment group, and a normal control group. EAE was induced in the mice with and without ulinastatin treatment. Demyelination was evaluated, as was the number of oligodendrocytes. The ulinastatin treatment group had a significantly lower clinical score, demyelinating score, and large numbers of oligodendrocytes compared with the group without ulinastatin treatment. Furthermore, ulinastatin treatment increased the expression of nerve growth factor and brain-derived neurotrophic factor, and protected against oligodendrocyte apoptosis. Thus, ulinastatin is shown to have a protective effect against EAE.
Similar content being viewed by others
Abbreviations
- UTI:
-
Ulinastatin
- OLG:
-
Oligodendrocytes
- MBP:
-
Myelin basic protein
- IF:
-
Immunofluorescence
- NGF:
-
Nerve growth factor
- BDNF:
-
Brain-derived neurotrophic factor
- CNPase:
-
2′,3′-cyclic nucleotide 3′-phosphodiesterase
- proNGF:
-
The precursor form of NGF
- TUNEL:
-
Terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate nick-end labeling
- BBB:
-
Blood-brain barrier
References
Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lassmann H (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128:2705–2712
Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707–717
Bjartmar C, Wujek JR, Trapp BD (2003) Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 206:165–171
Cudrici C, Niculescu T, Niculescu F, Shin ML, Rus H (2006) Oligodendrocyte cell death in pathogenesis of multiple sclerosis: protection of oligodendrocytes from apoptosis by complement. J Rehabil Res Dev 43:123–132
Hisahara S, Araki T, Sugiyama F, Yagami K, Suzuki M, Abe K, Yamamura K, Miyazaki J, Momoi T, Saruta T, Bernard CC, Okano H, Miura M (2000) Targeted expression of baculovirus p35 caspase inhibitor in oligodendrocytes protects mice against autoimmune-mediated demyelination. EMBO J 19:341–348
Skihar V, Silva C, Chojnacki A, Doring A, Stallcup WB, Weiss S, Yong VW (2009) Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate. Proc Natl Acad Sci USA 106:17992–17997
Chen CC, Wang SS, Lee FY (2007) Action of antiproteases on the inflammatory response in acute pancreatitis. JOP 8:488–494
Abe H, Sugino N, Matsuda T, Kanamaru T, Oyanagi S, Mori H (1996) Effect of ulinastatin on delayed neuronal death in the gerbil hippocampus. Masui 45:38–43
Yano T, Anraku S, Nakayama R, Ushijima K (2003) Neuroprotective effect of urinary trypsin inhibitor against focal cerebral ischemia-reperfusion injury in rats. Anesthesiology 98:465–473
Koga Y, Fujita M, Tsuruta R, Koda Y, Nakahara T, Yagi T, Aoki T, Kobayashi C, Izumi T, Kasaoka S, Yuasa M, Maekawa T (2010) Urinary trypsin inhibitor suppresses excessive superoxide anion radical generation in blood, oxidative stress, early inflammation, and endothelial injury in forebrain ischemia/reperfusion rats. Neurol Res 32:925–932
Tamatani M, Ogawa S, Nunez G, Tohyama M (1998) Growth factors prevent changes in Bcl-2 and Bax expression and neuronal apoptosis induced by nitric oxide. Cell Death Differ 5:911–919
Villoslada P, Hauser SL, Bartke I, Unger J, Heald N, Rosenberg D, Cheung SW, Mobley WC, Fisher S, Genain CP (2000) Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system. J Exp Med 191:1799–1806
Flugel A, Matsumuro K, Neumann H, Klinkert WE, Birnbacher R, Lassmann H, Otten U, Wekerle H (2001) Anti-inflammatory activity of nerve growth factor in experimental autoimmune encephalomyelitis: inhibition of monocyte transendothelial migration. Eur J Immunol 31:11–22
Althaus HH, Kloppner S, Schmidt-Schultz T, Schwartz P (1992) Nerve growth factor induces proliferation and enhances fiber regeneration in oligodendrocytes isolated from adult pig brain. Neurosci Lett 135:219–223
McTigue DM, Horner PJ, Stokes BT, Gage FH (1998) Neurotrophin-3 and brain-derived neurotrophic factor induce oligodendrocyte proliferation and myelination of regenerating axons in the contused adult rat spinal cord. J Neurosci 18:5354–5365
Cohen RI, Marmur R, Norton WT, Mehler MF, Kessler JA (1996) Nerve growth factor and neurotrophin-3 differentially regulate the proliferation and survival of developing rat brain oligodendrocytes. J Neurosci 16:6433–6442
Lee R, Kermani P, Teng KK, Hempstead BL (2001) Regulation of cell survival by secreted proneurotrophins. Science 294:1945–1948
Beattie MS, Harrington AW, Lee R, Kim JY, Boyce SL, Longo FM, Bresnahan JC, Hempstead BL, Yoon SO (2002) ProNGF induces p75-mediated death of oligodendrocytes following spinal cord injury. Neuron 36:375–386
Coulson EJ, Reid K, Murray SS, Cheema SS, Bartlett PF (2000) Role of neurotrophin receptor p75NTR in mediating neuronal cell death following injury. Clin Exp Pharmacol Physiol 27:537–541
Zhang J, Brodie C, Li Y, Zheng X, Roberts C, Lu M, Gao Q, Borneman J, Savant-Bhonsale S, Elias SB, Chopp M (2009) Bone marrow stromal cell therapy reduces proNGF and p75 expression in mice with experimental autoimmune encephalomyelitis. J Neurol Sci 279:30–38
Chen X, Pi R, Zou Y, Liu M, Ma X, Jiang Y, Mao X, Hu X (2010) Attenuation of experimental autoimmune encephalomyelitis in C57 BL/6 mice by osthole, a natural coumarin. Eur J Pharmacol 629:40–46
Kuerten S, Kostova-Bales DA, Frenzel LP, Tigno JT, Tary-Lehmann M, Angelov DN, Lehmann PV (2007) MP4- and MOG:35–55-induced EAE in C57BL/6 mice differentially targets brain, spinal cord and cerebellum. J Neuroimmunol 189:31–40
Morimoto T, Sasaki T, Takakura K (1992) Effect of ulinastatin on postischemic brain edema in cats. No To Shinkei 44:337–341
Munakata M, Kato R, Yokoyama H, Haginoya K, Tanaka Y, Kayaba J, Kato T, Takayanagi R, Endo H, Hasegawa R, Ejima Y, Hoshi K, Iinuma K (2000) Combined therapy with hypothermia and anticytokine agents in influenza A encephalopathy. Brain Dev 22:373–377
HG DU, Yin LC, He M, Zhang GJ, Tian Y, Wang C, GA DU (2005) Application of ulinastatin in severe craniocerebral injuries. Chin J Traumatol 8:236–239
Cowan WM (2001) Viktor Hamburger and Rita Levi-Montalcini: the path to the discovery of nerve growth factor. Annu Rev Neurosci 24:551–600
Sugiki M, Sumi H, Maruyama M, Yoshida E, Mihara H (1989) Clearance and distribution of acid-stable trypsin inhibitor (ASTI). Enzyme 42:31–38
Keegan BM, Noseworthy JH (2002) Multiple sclerosis. Annu Rev Med 53:285–302
Weiss N, Miller F, Cazaubon S, Couraud PO (2009) The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta 1788:842–857
Ma X, Jiang Y, Wu A, Chen X, Pi R, Liu M, Liu Y (2010) Berberine attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice. PLoS One 5:e13489
Lassmann H, Schwerer B, Kitz K, Egghart M, Bernheimer H (1983) Pathogenetic aspects of demyelinating lesions in chronic relapsing experimental allergic encephalomyelitis: possible interaction of cellular and humoral immune mechanisms. Prog Brain Res 59:305–315
Wu YJ, Ling Q, Zhou XH, Wang Y, Xie HY, Yu JR, Zheng SS (2009) Urinary trypsin inhibitor attenuates hepatic ischemia-reperfusion injury by reducing nuclear factor-kappa B activation. Hepatobiliary Pancreat Dis Int 8:53–58
Li XK, Matin AF, Suzuki H, Uno T, Yamaguchi T, Harada Y (1993) Effect of protease inhibitor on ischemia/reperfusion injury of the rat liver. Transplantation 56:1331–1336
Chen CC, Liu ZM, Wang HH, He W, Wang Y, Wu WD (2004) Effects of ulinastatin on renal ischemia-reperfusion injury in rats. Acta Pharmacol Sin 25:1334–1340
Ren B, Wu H, Zhu J, Li D, Shen Y, Ying R, Dong G, Jing H (2006) Ulinastatin attenuates lung ischemia-reperfusion injury in rats by inhibiting tumor necrosis factor alpha. Transplant Proc 38:2777–2779
Kobayashi H, Suzuki M, Tanaka Y, Hirashima Y, Terao T (2001) Suppression of urokinase expression and invasiveness by urinary trypsin inhibitor is mediated through inhibition of protein kinase C- and MEK/ERK/c-Jun-dependent signaling pathways. J Biol Chem 276:2015–2022
Shikimi T, Hattori K, Takaori S (1992) Existence of a human urinary trypsin inhibitor (urinastatin)-like substance in the rat brain. Jpn J Pharmacol 60:97–103
Shikimi T, Wessel T, Joh TH, Takahashi M, Kaneto H, Hattori K, Takaori S (1993) Demonstration of a human urinary trypsin inhibitor (urinastatin)-like substance in the murine brain. Brain Res 616:230–235
Iwama H, Ohmori S, Tsutsumi T (2000) Detectable concentrations of urinary trypsin inhibitor in cerebrospinal fluid. J Neurosurg Anesthesiol 12:29–32
Monard D (1988) Cell-derived proteases and protease inhibitors as regulators of neurite outgrowth. Trends Neurosci 11:541–544
Acknowledgments
This study was supported by the Science and Technology Program of Guangdong Province (No. 2008A030201027).
Author information
Authors and Affiliations
Corresponding author
Additional information
Yaqing Shu and Yu Yang are contributed equally to this work.
Rights and permissions
About this article
Cite this article
Shu, Y., Yang, Y., Qiu, W. et al. Neuroprotection by Ulinastatin in Experimental Autoimmune Encephalomyelitis. Neurochem Res 36, 1969–1977 (2011). https://doi.org/10.1007/s11064-011-0520-4
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11064-011-0520-4